Nature Medicine
2, 523 - 524 (1996)
doi:10.1038/nm0596-523
The cost of treating Gaucher diseaseErnest BeutlerThe Scripps Research Institute, 10666 North Torrey Pines Road, La Jolla, California 92037, USA Treatments fashioned specifically for rare diseases are necessarily very expensive. A fully satisfactory solution to this problem has not yet been found.
REFERENCES
- Gaucher disease: Current issues in diagnosis and treatment. Natl. Inst. Health Technol. Assess. Statement. February 27−March 1, 1−27 (1995).
- Robinson, M.L. & Craig, C. Company retires $100M debt. Genzyme's Ceredase hits financial constraints. BioWorld Today 7, 1 (1996). | ChemPort |
- Zimran, A. et al. Low-dose enzyme replacement therapy for Gaucher's disease: Effects of age, sex, genotype, and clinical features on response to treatment. Am. J. Med. 97, 3−13 (1994). | Article | PubMed | ISI | ChemPort |
- Balicki, D. & Beutler, E. Gaucher disease. Medicine (Baltimore) 74, 305−323 (1995). | Article | PubMed | ChemPort |
- Beutler, E. Treatment regimens in Gaucher's disease. Lancet 346, 581−582 (1995). | Article | PubMed | ISI | ChemPort |
- Beutler, E. et al. The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol. Dis. 21, 86−108 (1995). | Article | PubMed | ISI | ChemPort |
- Hollak, C.E.M. et al. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 345, 1474−1478 (1995). | Article | PubMed | ISI | ChemPort |
- Cohen, Y., Elstein, D., Abrahamov, A., Hirsch, H. & Zimran, A. HCG contamination of alglucerase: Clinical implications in low-dose regimen. Am. J. Hematol. 47, 235−236 (1994). | PubMed | ISI | ChemPort |
|
